Skip to main content
. 2015 Jan 30;6(3):1695–1706. doi: 10.18632/oncotarget.2713

Figure 3. The impacts of key residues as well as the therapeutic antibodies on ErbB2 dimerization and phosphorylation.

Figure 3

(A) Crosslinking and immunoblotting assays for key residues of the homophilic ErbB2 interaction interface. (B) Co-immunoprecipitation assay for key residues of the homophilic ErbB2 interaction interface. (C) and (D) Pertuzumab, but not trastuzumab, sterically interferes with ErbB2 homodimerization in the co-immunoprecipitation assay.